L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.6 NOK 4.48% Market Closed
Market Cap: 382.3m NOK

P/OCF
Price to OCF

-5.4
Current
-4.8
Median
19.2
Industry
Lower than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-5.4
=
Market Cap
381.7m NOK
/
Operating Cash Flow
-70.4m NOK
Market Cap P/OCF
NO
Lytix Biopharma AS
OSE:LYTIX
381.7m NOK -5.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -222 137.2
US
Abbvie Inc
NYSE:ABBV
325.9B USD 17.3
US
Amgen Inc
NASDAQ:AMGN
143B USD 11.7
US
Gilead Sciences Inc
NASDAQ:GILD
120.7B USD 11.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.2B USD -111.4
US
Epizyme Inc
F:EPE
94.1B EUR -506.4
AU
CSL Ltd
ASX:CSL
115.9B AUD 25.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
57.1B USD 14.4
US
Seagen Inc
F:SGT
39.3B EUR -81.7
NL
argenx SE
XBRU:ARGX
30.3B EUR -409.2
 
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average P/OCF: 16.1
Negative Multiple: -5.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 137.2
US
Abbvie Inc
NYSE:ABBV
17.3
US
Amgen Inc
NASDAQ:AMGN
11.7
US
Gilead Sciences Inc
NASDAQ:GILD
11.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -111.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -506.4
AU
CSL Ltd
ASX:CSL
25.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -81.7
NL
argenx SE
XBRU:ARGX
Negative Multiple: -409.2

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A